Carregant...
Relapsed disease and aspects of undetectable MRD and treatment discontinuation
Continuous treatment vs fixed duration of monotherapies and combinations of targeted agents are treatment options in relapsed chronic lymphocytic leukemia. The optimal choice of relapse treatment is dependent on the prior frontline therapy, duration of remission after frontline, genetic markers, and...
Guardat en:
| Publicat a: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913464/ https://ncbi.nlm.nih.gov/pubmed/31808867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000070 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|